CYBIN INC.
HELP evidence brief
What we can confirm
- Market Cap:
- $938.2M
What it means
What to watch
Prepared research question
What matters most for HELP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HELP
Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health disorders, with a lead program in Phase 3 for major depressive disorder.
Key risk: Binary Phase 3 outcome
Market Cap
$938.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health disorders, with a lead program in Phase 3 for major depressive disorder.
- Helus Pharma (formerly Cybin Inc.) completed its legal name change to Helus Pharma Inc. effective October 1, 2026 [news].
- The company expects a pivotal Phase 3 readout for HLP003 in adjunctive major depressive disorder in Q4 2026 [news].
- Phase 2a study of CYB004 for generalized anxiety disorder started in May 2024 [catalyst].
- Phase 3 trials for CYB003 in major depressive disorder started in December 2024 and July 2025 [catalyst].
- CEO Michael Halstead was appointed in 2026 and has been presenting at investor conferences [news].
What works
- The company has multiple late-stage clinical programs, including a Phase 3 trial for HLP003 in MDD expected to read out in Q4 2026 [news].
- Helus Pharma is developing novel serotonergic agonists, a differentiated approach in mental health [news].
- The company has attracted investor attention, with a reported 1-month share price return of 83.53% as of August 2026 [news].
What to weigh
- The company is pre-revenue and clinical-stage, with no approved products, making it dependent on trial outcomes [news].
- The Phase 3 readout for HLP003 is a binary catalyst; failure could significantly impact the company's outlook [news].
- The company recently changed its name from Cybin to Helus Pharma, which may cause short-term brand confusion [news].
From the filings
Quoted directly from source documents.
The company completed its legal name change to Helus Pharma Inc. effective October 1, 2026.
“the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026.”
News · October 1, 2026
Helus Pharma expects a pivotal Phase 3 readout for HLP003 in Q4 2026.
“the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter”
News · September 21, 2026
Phase 2a study of CYB004 for GAD started in May 2024.
“Phase2_Start: A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)”
Catalysts · May 10, 2024
Phase 3 trials for CYB003 in MDD started in December 2024 and July 2025.
“Phase3_Start: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder”
Catalysts · December 17, 2024
Catalyst timeline
- 2024-05-10 · Phase 2a start for CYB004 in GAD — A randomized, double-blind, active-controlled study to assess efficacy, safety, and PK of CYB004 in GAD.
- 2024-12-17 · Phase 3 start for CYB003 in MDD — A placebo-controlled, randomized, double-blind trial of oral CYB003 for MDD.
- 2025-07-18 · Phase 3 long-term extension for CYB003 in MDD — A long-term extension trial with optional additional doses to assess safety and long-term efficacy in MDD.
Risks & what to watch (3)›
Key risks
- Binary Phase 3 outcome — The Q4 2026 HLP003 readout is a pivotal catalyst; failure could severely impact the company's valuation and pipeline [news].
- Pre-revenue stage — As a clinical-stage company with no approved products, Helus Pharma relies on trial success and funding [news].
- Name change confusion — The recent rebranding from Cybin to Helus Pharma may cause short-term market confusion [news].
What to watch
- Q4 2026 Phase 3 readout for HLP003 in adjunctive MDD [news].
- Regulatory and clinical developments for CYB004 in GAD [catalyst].
- Progress of CYB003 Phase 3 trials in MDD [catalyst].
- Investor sentiment and share price movements following the name change and trial milestones [news].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run CYBIN INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CYBIN INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Frequently asked questions
What is the AI investment thesis for CYBIN INC.?
Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health disorders, with a lead program in Phase 3 for major depressive disorder.
Who is the CEO of CYBIN INC.?
Mr. Michael I. Halstead J.D. is the chief executive officer of CYBIN INC. (HELP).
Where is CYBIN INC. headquartered?
CYBIN INC. (HELP) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.